Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 12:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 1,412 matching trials from the live ClinicalTrials.gov search.
Conditions
DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma, Refractory Multiple Myeloma, Smoldering Multiple Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Lenalidomide, Melphalan, Peripheral Blood Stem Cell Transplantation, Placebo Administration
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2027
U.S. locations
140
States / cities
Scottsdale, Arizona • Duarte, California • Sacramento, California + 103 more
Conditions
Substance-Related Disorders, Depression, Stress Disorders, Post-Traumatic, Child Abuse, Child Neglect
Interventions
Wraparound
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
4
States / cities
Claremont, New Hampshire • Lebanon, New Hampshire
Conditions
Fanconi Anemia
Interventions
Anti-Thymocyte Globulin, Cyclophosphamide, Fludarabine, Hematopoietic Stem Cell Transplantation, Methylprednisolone, Filgrastim, Cyclosporine, Mycophenolate Mofetil
Biological · Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 59 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Active, not recruiting No phase listed Observational

Persona IQ Cohort Study

NCT06089291
Conditions
Osteo Arthritis Knee, Knee Arthritis, Monitoring Orthopedic Devices, Total Knee Arthroplasty, Total Knee Replacement
Interventions
Persona IQ
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Granger, Indiana • St Louis, Missouri • Charlotte, North Carolina + 1 more
Conditions
Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
busulfan, carboplatin, carmustine, cyclophosphamide, etoposide, melphalan, thiotepa, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
4 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Completed Not applicable Interventional Results available

Treatment Preference and Patient Centered Prostate Cancer Care

NCT02032550
Conditions
Prostate Cancer
Interventions
Preference Based Decision Aid
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Male only
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Conditions
Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia, T-Large Granulocytic Leukemia, T-Lymphoblastic Leukemia/Lymphoma, Peripheral T-Cell Lymphoma
Interventions
Romidepsin, Busulfan, Fludarabine, Stem Cell Transplant, Thymoglobulin
Drug · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Thrombotic Microangiopathy
Interventions
Ravulizumab, Best Supportive Care
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
8
States / cities
Tucson, Arizona • Aurora, Colorado • Atlanta, Georgia + 5 more
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
cyclophosphamide, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neuroblastoma
Interventions
Biopsy Procedure, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Clinical Observation, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Magnetic Resonance Imaging, Ultrasound
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 18 Months
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
193
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 147 more
Conditions
Acute Myeloblastic Leukemia
Interventions
Clofarabine/Busulfan x 4, Peripheral blood stem cell transplant
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
2 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Duarte, California • Kansas City, Kansas + 7 more
Conditions
Infection, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, pneumococcal polyvalent vaccine, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes, carmustine, cyclophosphamide, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Conditions
Lymphoma, B-cell Non-Hodgkin's Lymphoma
Interventions
Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 72 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, recombinant interferon alfa, busulfan, cyclophosphamide, melphalan, pamidronate disodium, thalidomide, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Up to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • Duarte, California
Conditions
Leukemia, B-cell, Lymphoma, Hodgkins, Lymphoma, Non-hodgkins, Lymphoma, B-Cell
Interventions
Allogeneic stem cell transplant, Anti-CD19-chimeric-antigen-receptor-transduced T cells, Leukapheresis
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Conditions
Brain and Central Nervous System Tumors, Kidney Cancer, Liver Cancer, Retinoblastoma, Sarcoma
Interventions
filgrastim, busulfan, etoposide, ifosfamide, melphalan, thiotepa, stem cell transplantation, tomotherapy, total marrow irradiation, Mesna, Whole lung radiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Recurrent Plasma Cell Myeloma
Interventions
Daratumumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Houston, Texas
Active, not recruiting Phase 2 Interventional Results available

KRDI in Transplant-Eligible MM

NCT04430894
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Isatuximab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Lymphoma
Interventions
filgrastim, monoclonal antibody Lym-1, cyclosporine, paclitaxel, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody Lym-1, yttrium Y 90 monoclonal antibody Lym-1
Biological · Drug · Procedure + 1 more
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Sacramento, California
Conditions
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Childhood Acute Myeloid Leukemia in Remission, Childhood Myelodysplastic Syndromes, de Novo Myelodysplastic Syndromes, Essential Thrombocythemia, Myelodysplastic Syndrome With Isolated Del(5q), Polycythemia Vera, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Secondary Myelofibrosis, Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions
cyclophosphamide, busulfan, tacrolimus, methotrexate, cytogenetic analysis, flow cytometry, pharmacological study, pharmacogenomic studies, peripheral blood stem cell transplantation, allogeneic hematopoietic stem cell transplantation
Drug · Genetic · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD), Metabolic Associated-dysfunction Steatohepatitis (MASH)
Interventions
Standard of care acceptance-based behavioral weight loss program, Occupational therapy dietary and lifestyle modifications
Behavioral
Lead sponsor
Grand Valley State University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Wyoming, Michigan
Conditions
Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma, Stage 2A Neuroblastoma, Stage 2B Neuroblastoma, Stage 3 Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, External Beam Radiation Therapy, Filgrastim, Laboratory Biomarker Analysis, Melphalan, Mesna, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Topotecan Hydrochloride, Vincristine Sulfate
Procedure · Drug · Radiation + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
113
States / cities
Birmingham, Alabama • Downey, California • Duarte, California + 90 more
Conditions
Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
filgrastim, carboplatin, etoposide, ifosfamide, paclitaxel, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
15 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2009
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Accepts healthy volunteers

The Counselor Led Resident Wellness Study

NCT07053111
Conditions
Burnout, Healthcare Workers, Anxiety, Wellness Program, Depression Not Otherwise Specified
Interventions
Wellness Intervention
Behavioral
Lead sponsor
University of Nevada, Reno
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Reno, Nevada